David Robert Vincent

Array ( [id] => 16711970 [patent_doc_number] => 20210079117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same [patent_app_type] => utility [patent_app_number] => 16/984287 [patent_app_country] => US [patent_app_date] => 2020-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43754 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16984287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628780 [patent_doc_number] => 20210047433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 16/984509 [patent_app_country] => US [patent_app_date] => 2020-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16984509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570685 [patent_doc_number] => 20210009691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/944816 [patent_app_country] => US [patent_app_date] => 2020-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16944816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710474 [patent_doc_number] => 20210077621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => METHODS FOR INHIBITING FIBROSIS IN A SUBJECT IN NEED THEREOF [patent_app_type] => utility [patent_app_number] => 16/917157 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711969 [patent_doc_number] => 20210079116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => METHODS FOR REDUCING PROTEINURIA IN A HUMAN SUBJECT SUFFERING FROM IMMUNOGLOBULIN A NEPHROPATHY [patent_app_type] => utility [patent_app_number] => 16/911682 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16911682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506421 [patent_doc_number] => 20200385677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/907374 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16907374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734755 [patent_doc_number] => 20220220214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => APJ MODULATORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/615546 [patent_app_country] => US [patent_app_date] => 2020-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790518 [patent_doc_number] => 20220249609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => COMBINATION THERAPY WITH CD13-TARGETED CHIMERIC PROTEINS OR CHIMERIC PROTEIN COMPLEXES [patent_app_type] => utility [patent_app_number] => 17/620329 [patent_app_country] => US [patent_app_date] => 2020-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43833 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16341723 [patent_doc_number] => 20200306373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => COMBINATION THERAPY OF TUMOR TARGETED ICOS AGONISTS WITH T-CELL BISPECIFIC MOLECULES [patent_app_type] => utility [patent_app_number] => 16/903756 [patent_app_country] => US [patent_app_date] => 2020-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62754 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16903756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17911747 [patent_doc_number] => 20220314142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => IMPROVEMENTS TO WASH SOLUTIONS FOR PROTEIN A CHROMATOGRAPHY IN AN ANTIBODY PURIFICATION PROCESS [patent_app_type] => utility [patent_app_number] => 17/620148 [patent_app_country] => US [patent_app_date] => 2020-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19273277 [patent_doc_number] => 12023384 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Immunogenic peptides comprising an MHC class II T cell epitope and a redox motif [patent_app_type] => utility [patent_app_number] => 16/892588 [patent_app_country] => US [patent_app_date] => 2020-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 19053 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16892588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19181031 [patent_doc_number] => 11987613 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-21 [patent_title] => Isolated T cell receptors and methods of use therefor [patent_app_type] => utility [patent_app_number] => 16/876419 [patent_app_country] => US [patent_app_date] => 2020-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 37 [patent_no_of_words] => 27134 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16876419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525517 [patent_doc_number] => 20200399597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 15/930571 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13899 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807726 [patent_doc_number] => 20220259561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => REGULATORY T CELLS TARGETED BY LYMPHOTOXIN ALPHA BLOCKING AGENT AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/610325 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657462 [patent_doc_number] => 20210054098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 15/930053 [patent_app_country] => US [patent_app_date] => 2020-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91165 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638179 [patent_doc_number] => 12168780 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => T cell receptor-deficient t cell compositions [patent_app_type] => utility [patent_app_number] => 16/872438 [patent_app_country] => US [patent_app_date] => 2020-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14026 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16872438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19291808 [patent_doc_number] => 12031156 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-09 [patent_title] => T cell receptor-deficient T cell compositions [patent_app_type] => utility [patent_app_number] => 16/872419 [patent_app_country] => US [patent_app_date] => 2020-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14029 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 275 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16872419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16793012 [patent_doc_number] => 20210122829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => MONOCLONAL ANTIBODY AND A METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 16/862417 [patent_app_country] => US [patent_app_date] => 2020-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14601 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343639 [patent_doc_number] => 20200308289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => THYMIC STROMAL LYMPHOPOIETIN RECEPTOR-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME [patent_app_type] => utility [patent_app_number] => 16/860216 [patent_app_country] => US [patent_app_date] => 2020-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16860216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612141 [patent_doc_number] => 20210030794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => GAMMA DELTA T CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/859954 [patent_app_country] => US [patent_app_date] => 2020-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16859954 [rel_patent_id] =>[rel_patent_doc_number] =>)